Back

Role of liraglutide on cardiotoxicity and gut microbiota changes induced by doxorubicin in rats

30 August 2024 (13:00 - 13:50)
Organised by: Logo
Congress Presentation Part of: Cardiovascular complications in cardio-oncology: risk assessment Cardio-Oncology ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Carolina Rodrigues Tonon

Faculty of Medicine of Botucatu, UNESP, Botucatu (Brazil)

8 More presentations in this session

Presentation thumbnail
The prognostic significance of Weber and ventilatory CPET classifications in amyloidosis patients
Doctor S. Santos Patarroyo (Rochester, US) Doctor L. Ortega Aviles (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Assessment of poor cardiovascular health metrics and related disparities among cancer patients in the United States: a nationwide analysis of over 1.5 million individuals
Doctor S. Abohashem (Boston, US)
Abstract Slides Video
Presentation thumbnail
A study to assess the ability of the HFA-ICOS risk stratification tool to predict cancer therapy-related cardiac dysfunction for patients receiving anthracycline chemotherapy.
Doctor A. Byrne (Godalming, GB)
Abstract Slides Video
Presentation thumbnail
Cardiovascular effects of BRAF and MEK inhibitors in patients with melanoma: a prospective study incorporating risk scores, cardiac biomarkers and cardiovascular magnetic resonance imaging
Doctor C. Glen (Glasgow, GB)
Abstract Slides Video
Presentation thumbnail
Real-world analysis of transcatheter aortic valve replacement in patients with prostate cancer and severe aortic stenosis
Doctor R. Belo Nunes (Sao Paulo, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular complications in cardio-oncology: risk assessment

The Event

Event poster

ESC Congress 2024

30 August 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Influence of the 3-omega fatty acids supplementation on the structure, regulation and vascular function of rats chronically treated with doxorubicin
thumbnail
Congress Presentation
Sodium-glucose cotransporter 2 inhibitor Dapagliflozin reduces systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity
thumbnail
Congress Presentation
MyD-88/NLRP-3 inhibition by dapagliflozin protects against anthracycline and trastuzumab cardiotoxicity in preclinical models

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources